Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Drawing on the film Wonder, this article examines how a narrative of community acceptance offers sustaining relationships for people with unusual facial appearance.
AMA J Ethics. 2019;21(11):E1003-1008. doi:
10.1001/amajethics.2019.1003.
Michael Anderson, PhD and Susan Leigh Anderson, PhD
Two concerns (unknowability of how output is derived from input and overreliance on clinical decision support systems) are main sources of ethical questions about AI in health care.
AMA J Ethics. 2019;21(2):E125-130. doi:
10.1001/amajethics.2019.125.
Considering chronic opioid use when planning elective surgery would likely enhance team communication, decrease stigma, and facilitate care transitioning and long-term planning.
AMA J Ethics. 2020;22(8):E664-667. doi:
10.1001/amajethics.2020.664.
Pathologists should work cooperatively with clinicians and provide guidance about appropriate testing to uphold the medical ethics principle of justice.
AMA J Ethics. 2016;18(8):793-799. doi:
10.1001/journalofethics.2016.18.8.ecas5-1608.